Ketorolac Tromethamine Injection
Product Images NDC 0487-6232

9 FDA label images from Nephron Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 0487-6232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton (Carton)

Carton (Carton)
The image shows a flattened carton label for Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), an intramuscular injection from Nephron Pharmaceuticals Corporation. The label includes usage instructions for intramuscular use only and packaging details for 30 single-dose 2 mL vials. The NDC number 0487-6232-01 is printed, along with manufacturer and regulatory information.*
FDA Label Image

Gi (Gi Experiences)

Gi (Gi Experiences)
A data table listing gastrointestinal (GI) and other reported adverse experiences associated with Ketorolac Tromethamine injection. Gastrointestinal symptoms include abdominal pain, constipation/diarrhea, dyspepsia, flatulence, GI fullness, GI ulcers, gross bleeding/perforation, heartburn, nausea, stomatitis, and vomiting. Other adverse experiences include abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating. Nausea and headaches have an incidence greater than 10%.*
FDA Label Image

Sleeve Label (Sleeve)

Sleeve Label (Sleeve)
Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL) single-dose vial label. For intramuscular use only, provided by Nephron Pharmaceuticals Corporation. The label includes storage conditions (20°C to 25°C, protected from light) and notes that the product is sterile and nonpyrogenic.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A data table presenting approximate average pharmacokinetic parameters with mean and standard deviation for ketorolac tromethamine administered orally, intramuscularly, and as an intravenous bolus. Parameters include Tmax, Cmax, Cmin, Cav, and volume of distribution for various doses in mg. Additional notes clarify study sources, sample sizes, and calculation methods.*
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
A data table showing the incidence of clinically serious gastrointestinal bleeding associated with different total daily doses of Ketorolac Tromethamine Injection. The table differentiates between adult patients with and without a history of gastrointestinal perforation, ulcer, or bleeding (PUB), further segmented by age groups under and over 65 years, and dose ranges from 60 mg or less to over 120 mg.*
FDA Label Image

Ifu

Ifu
Instructions for use of Ketorolac Tromethamine Injection, USP Luer-Lock Vial with seven steps illustrated, detailing vial cap removal, drawing plunger back on syringe, connecting syringe to vial with luer-lock, charging vial with air, orienting syringe and drawing product, disconnecting and reconnecting syringe, and discarding unused portion.*
FDA Label Image

Luer Lock

Luer Lock
An illustration showing a Luer-Lock syringe connected to a plastic Luer-Lock vial. The syringe is labeled and designed for use with the vial, commonly used for intramuscular injections.*
FDA Label Image

Figure 1 (Structure)

Figure 1 (Structure)
Chemical structure of Ketorolac Tromethamine, showing its molecular components and formula C15H13NO3 · C4H11NO3.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
A data table titled "The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac Tromethamine (Intramuscular and Oral) in Adult Populations." It presents mean and range values of total clearance (in L/h/kg) and terminal half-life (in hours) for different subject groups, comparing intramuscular and oral routes for ketorolac tromethamine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.